Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma

W. R. Shapiro, S. B. Green, P. C. Burger, M. S. Mahaley, R. G. Selker, J. C. VanGilder, J. T. Robertson, J. Ransohoff, J. Mealey, T. A. Strike, D. A. Pistenmaa

Research output: Contribution to journalArticle

368 Citations (Scopus)

Abstract

Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of these chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin). Patients accrued in 1980 and 1981 were to receive 6020 rads of whole-brain radiotherapy concurrent with the first course of chemotherapy. Patients accrued in 1982 and 1983 were randomly assigned to receive either whole-brain irradiation as above, or 4300 rads of whole-brain radiotherapy plus 1720 rads coned down to the tumor volume. The data were analyzed for the total randomized population and separately for the 510 patients, termed the 'Valid Study Group (VSG)', who met protocol eligibility specifications (including central pathology review), 80% of whom had glioblastoma multiforme. The median survival times from time of randomization for the three chemotherapy groups of the VSG ranged from 11.3 to 13.8 months, and 29% to 37% of the patients survived for 18 months (life-table estimate); the differences between these groups were not statistically significant. Survival differences between the radiotherapy groups were small and not statistically significant. It is concluded that, for malignant glioma, giving part of the radiotherapy by coned-down boost is as effective as full whole-brain irradiation, and that multiple-drug chemotherapy as outlined in this protocol conferred no significant survival advantage over BCNU alone.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Neurosurgery
Volume71
Issue number1
StatePublished - 1989

Fingerprint

Carmustine
Glioma
Radiotherapy
Drug Therapy
Procarbazine
Brain
Survival
Teniposide
Podophyllotoxin
Therapeutics
Life Tables
Hydroxyurea
Glioblastoma
Random Allocation
Tumor Burden
Pathology
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., ... Pistenmaa, D. A. (1989). Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Journal of Neurosurgery, 71(1), 1-9.

Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. / Shapiro, W. R.; Green, S. B.; Burger, P. C.; Mahaley, M. S.; Selker, R. G.; VanGilder, J. C.; Robertson, J. T.; Ransohoff, J.; Mealey, J.; Strike, T. A.; Pistenmaa, D. A.

In: Journal of Neurosurgery, Vol. 71, No. 1, 1989, p. 1-9.

Research output: Contribution to journalArticle

Shapiro, WR, Green, SB, Burger, PC, Mahaley, MS, Selker, RG, VanGilder, JC, Robertson, JT, Ransohoff, J, Mealey, J, Strike, TA & Pistenmaa, DA 1989, 'Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma', Journal of Neurosurgery, vol. 71, no. 1, pp. 1-9.
Shapiro, W. R. ; Green, S. B. ; Burger, P. C. ; Mahaley, M. S. ; Selker, R. G. ; VanGilder, J. C. ; Robertson, J. T. ; Ransohoff, J. ; Mealey, J. ; Strike, T. A. ; Pistenmaa, D. A. / Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. In: Journal of Neurosurgery. 1989 ; Vol. 71, No. 1. pp. 1-9.
@article{5425b570009b4e2f9977d851789424af,
title = "Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma",
abstract = "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of these chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin). Patients accrued in 1980 and 1981 were to receive 6020 rads of whole-brain radiotherapy concurrent with the first course of chemotherapy. Patients accrued in 1982 and 1983 were randomly assigned to receive either whole-brain irradiation as above, or 4300 rads of whole-brain radiotherapy plus 1720 rads coned down to the tumor volume. The data were analyzed for the total randomized population and separately for the 510 patients, termed the 'Valid Study Group (VSG)', who met protocol eligibility specifications (including central pathology review), 80{\%} of whom had glioblastoma multiforme. The median survival times from time of randomization for the three chemotherapy groups of the VSG ranged from 11.3 to 13.8 months, and 29{\%} to 37{\%} of the patients survived for 18 months (life-table estimate); the differences between these groups were not statistically significant. Survival differences between the radiotherapy groups were small and not statistically significant. It is concluded that, for malignant glioma, giving part of the radiotherapy by coned-down boost is as effective as full whole-brain irradiation, and that multiple-drug chemotherapy as outlined in this protocol conferred no significant survival advantage over BCNU alone.",
author = "Shapiro, {W. R.} and Green, {S. B.} and Burger, {P. C.} and Mahaley, {M. S.} and Selker, {R. G.} and VanGilder, {J. C.} and Robertson, {J. T.} and J. Ransohoff and J. Mealey and Strike, {T. A.} and Pistenmaa, {D. A.}",
year = "1989",
language = "English (US)",
volume = "71",
pages = "1--9",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma

AU - Shapiro, W. R.

AU - Green, S. B.

AU - Burger, P. C.

AU - Mahaley, M. S.

AU - Selker, R. G.

AU - VanGilder, J. C.

AU - Robertson, J. T.

AU - Ransohoff, J.

AU - Mealey, J.

AU - Strike, T. A.

AU - Pistenmaa, D. A.

PY - 1989

Y1 - 1989

N2 - Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of these chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin). Patients accrued in 1980 and 1981 were to receive 6020 rads of whole-brain radiotherapy concurrent with the first course of chemotherapy. Patients accrued in 1982 and 1983 were randomly assigned to receive either whole-brain irradiation as above, or 4300 rads of whole-brain radiotherapy plus 1720 rads coned down to the tumor volume. The data were analyzed for the total randomized population and separately for the 510 patients, termed the 'Valid Study Group (VSG)', who met protocol eligibility specifications (including central pathology review), 80% of whom had glioblastoma multiforme. The median survival times from time of randomization for the three chemotherapy groups of the VSG ranged from 11.3 to 13.8 months, and 29% to 37% of the patients survived for 18 months (life-table estimate); the differences between these groups were not statistically significant. Survival differences between the radiotherapy groups were small and not statistically significant. It is concluded that, for malignant glioma, giving part of the radiotherapy by coned-down boost is as effective as full whole-brain irradiation, and that multiple-drug chemotherapy as outlined in this protocol conferred no significant survival advantage over BCNU alone.

AB - Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of these chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin). Patients accrued in 1980 and 1981 were to receive 6020 rads of whole-brain radiotherapy concurrent with the first course of chemotherapy. Patients accrued in 1982 and 1983 were randomly assigned to receive either whole-brain irradiation as above, or 4300 rads of whole-brain radiotherapy plus 1720 rads coned down to the tumor volume. The data were analyzed for the total randomized population and separately for the 510 patients, termed the 'Valid Study Group (VSG)', who met protocol eligibility specifications (including central pathology review), 80% of whom had glioblastoma multiforme. The median survival times from time of randomization for the three chemotherapy groups of the VSG ranged from 11.3 to 13.8 months, and 29% to 37% of the patients survived for 18 months (life-table estimate); the differences between these groups were not statistically significant. Survival differences between the radiotherapy groups were small and not statistically significant. It is concluded that, for malignant glioma, giving part of the radiotherapy by coned-down boost is as effective as full whole-brain irradiation, and that multiple-drug chemotherapy as outlined in this protocol conferred no significant survival advantage over BCNU alone.

UR - http://www.scopus.com/inward/record.url?scp=0024312871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024312871&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 1

EP - 9

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 1

ER -